Did Johnson & Johnson's CFO Just Spell Trouble for Moderna and Pfizer?

[cafead]

via

• The pandemic isn't over, but the vaccine market's growth may be plateauing.
• Moderna could face crashing revenue in high-income markets.
• Pfizer will likely fare better than Moderna because its base of revenue is much more diversified.

article source